Phase 1 study of eprenetapopt plus venetoclax and azacitidine in TP53-mutated acute myeloid leukemia
Dr. David Sallman
TP53-mutated acute myeloid leukemia (AML) is associated with poor outcomes. Eprenetapopt (APR-246) is a first-in-class, small molecule p53 reactivator. multicenter phase 1 study in the USA found that among patients with TP53-mutated AML the combination of eprenetapopt with venetoclax and azacitidine had an acceptable safety profile and encouraging activity, with overall response rate 64% and complete response rate 38%..
